1. Why API Supplier Selection Is an IP and Valuation Decision, Not a Procurement Function Most pharmaceutical procurement teams still […]

Section 1: What Freedom to Operate Actually Means — and What It Does Not 1.1 The Core Definition Freedom to

The $300 Billion Map: Why the Patent Cliff Is Your Best Market Signal {#market-signal} A drug patent is two things

Section 1: The Strategic Foundations of Pharmaceutical Pricing The price of a new drug is not calculated. It is constructed.

1. What ‘Patent Pending’ Actually Means in Pharma IP Law ‘Patent pending’ describes a single administrative fact: a patent application

A deep-dive for pharma/biotech IP teams, portfolio managers, R&D leads, and institutional investors who need to move beyond 71% forecast

1. The Market Context: A $400 Billion Patent Cliff and What It Means for Generic Entrants Between 2025 and 2030,

The patent cliff is not a metaphor. It is a measurable revenue event. When a branded drug loses market exclusivity,

1. Why Late-Stage LCM Has Become a Board-Level Discipline The pharmaceutical industry is staring at its largest revenue destruction event